—

Liquidia Technologies Inc (LQDA) — Technical state

As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 47 out of 100 (momentum 31 · quality 68 · valuation 31), as of 2026-11-03.
  • Signal: Mixed moving-average stack — Trades -20.2% vs the 50-day and -22.9% vs the 200-day average, 55.3% below the 52-week high and +88.5% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes. (as of 2026-11-02)
  • Trend: Liquidia Technologies Inc trades 20.2% below its 50-day and 22.9% below its 200-day moving average. (as of 2026-11-02)

Liquidia Technologies develops and sells therapies for rare heart-and-lung diseases, mainly pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil, and it also sells Remodulin, an injected version of the same drug given through a pump.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the LQDA overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Mixed moving-average stack

Trades -20.2% vs the 50-day and -22.9% vs the 200-day average, 55.3% below the 52-week high and +88.5% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes.

Ranked #8 on today’s Directional Flow — Falling fastest list (scan of 2026-11-02).

The moving-average stack

FAQ · from the current data · as of 2026-11-02

Quick answers

What is the current Closelooknet signal on LQDA?

Mixed moving-average stack — Trades -20.2% vs the 50-day and -22.9% vs the 200-day average, 55.3% below the 52-week high and +88.5% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is LQDA above its 50-day and 200-day moving averages?

As of 2026-11-02, Liquidia Technologies Inc trades -20.2% below its 50-day and -22.9% below its 200-day average, with the 20-day +15.6% away.

How far is LQDA from its 52-week high?

55.3% below the 52-week high and 88.5% above the 52-week low, as of 2026-11-02.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.